Exp. Hematol. 2020 Jan 30
Clonal hematopoiesis in hematological disorders.
Swierczek S, Prchal JT
Clonality studies can establish the single cell origin of tumors and thus differentiate clonal malignant and premalignant processes from reactive poly ...
Read More
Source: PubMed
Exp. Hematol. 2020 Jan 30
Histone lysine demethylase KDM5B maintains chronic myeloid leukemia via multiple epigenetic actions.
Xue S, Lam YM, He Z, Zheng Y, Li L, Zhang Y, Li C, Mbadhi MN, Zheng L, Cheng Z, Liu Y, Wang X, Chan LC, Ng RK, Zhang J
Histone lysine demethylase KDM5 family is implicated in normal development and stem cell maintenance by epigenetic modulation of histone methylation s ...
Read More
Source: PubMed
Leukemia 2020 Jan 31
Correction: CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.
Kinstrie R, Horne GA, Morrison H, Irvine D, Munje C, Castañeda EG, Moka HA, Dunn K, Cassels JE, Parry N, Clarke CJ, Scott MT, Clark RE, Holyoake TL, Wheadon H, Copland M
An amendment to this paper has been published and can be accessed via a link at the top of the paper. ...
Read More
Source: PubMed
Br. J. Haematol. 2020 Jan 31
Distinctive and common features of moderate aplastic anaemia.
Patel BJ, Barot SV, Kuzmanovic T, Kerr C, Przychodzen BP, Thota S, Lee S, Patel S, Radivoyevitch T, Lichtin A, Advani A, Kalaycio M, Sekeres MA, Carraway HE, Maciejewski JP
The therapy algorithm for severe aplastic anaemia (sAA) is established but moderate AA (mAA), which likely reflects a more diverse pathogenic mechanis ...
Read More
Source: PubMed
Haematologica 2020 Jan 30
Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells.
Yahata T, Ibrahim AA, Hirano KI, Muguruma Y, Naka K, Hozumi K, Vaughan DE, Miyata T, Ando K
Therapeutic strategies that target leukemic stem cells (LSCs) provide potential advantages in the treatment of chronic myeloid leukemia (CML). Here, w ...
Read More
Source: PubMed
